E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated | |
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of Magne B6 versus Magnespasmyl (magnesium only) supplementation on stress level, evaluated by the stress subscale from the Depression Anxiety Stress Scale (DASS)-42 test, in chronically stressed subjects with suboptimal serum magnesium levels. |
|
E.2.2 | Secondary objectives of the trial |
-To compare the effect of Magne B6 versus Magnespasmyl supplementation on depression and anxiety subscales from the DASS-42 test.
-To compare the effect of Magne B6 versus Magnespasmyl supplementation on cortisol awakening response (CAR) measured over a 2-day period.
-To compare the effect of Magne B6 versus Magnespasmyl supplementation on magnesium levels in erythrocytes.
-Adverse events (AEs).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Male and female subjects aged between 18 and 50 years, chronically stressed (screening DASS-42 scale for chronic stress >18).
-Signed written informed consent.
-Moderate hypomagnesemic and low serum magnesium level subjects (0.5mmol/L <Mg serum levels <0.85mmol/L).
-Women must use an effective contraceptive method during the study period.
-Body mass index (BMI) >18.5 and ≤29.9 kg/m^2.
-Able to understand the study, including risks and adverse events; collaborating with Investigator and proceeding according with protocol.
|
|
E.4 | Principal exclusion criteria |
-Any technical/administrative reason (eg, subject homeless) that makes it impossible to randomize the patient in the study.
-Subject who has previously participated in any clinical trial of Magne B6 or Magnespasmyl.
-Subject who has taken other investigational drugs or prohibited therapy for this study within 3 months from screening.
-Conditions/situations such as:
-Subjects with conditions/concomitant diseases making them non evaluable for the primary endpoint.
-Requirement for concomitant treatment that could bias primary endpoint.
-Impossibility to meet specific protocol requirements (eg, for hospitalization).
-Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
-Subject not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions or subjects potentially at risk of noncompliance to study procedures.
-Subjects with severe hypomagnesemia (serum magnesium less than or equal to 0.45 mmol/L).
-Subjects with moderate and severe kidney failure.
-Subjects treated with Levodopa.
-Subjects treated with quinidine.
-Any known allergies to the test substances, or with fructose intolerance, glucose and galactose malabsorption syndrome or sucrase-isomaltase deficiency due to sucrose content (excipient).
-Any known addiction to drugs and alcohol.
-Alcohol intake of at least 3 drinks/day.
-Type 1 or 2 diabetes mellitus.
-Active neoplasms.
-Known hyperthyroidism unless treated and under control.
-History of hepatic, renal, pulmonary, gastrointestinal, neurologic, hematologic, psychiatric, cardiac, or allergic disease clinically relevant.
-Laboratory results out of the normal range. In this case, subject can be included if the alterations are considered by the doctor as not relevant.
-The subject has an excessive tobacco consumption (smokes more than 10 cigarettes/day).
-Have used regular medication for 2 weeks before the study, except contraceptive oral method for women.
-Hospitalization up to 8 weeks before the study start.
-Treatment within 3 months before the study starts with a drug considered toxic.
-Treatment with proton-pump inhibitors (eg, omeprazole, pantoprazole, esomeprazole, lansoprazole/dexlansoprazole, rabeprazole/dexrabeprazole)
-Subject which has donate or lost 450 mL or more of blood within 3 months before the study.
-Maintaining therapy with any drug, except contraceptive oral pills.
-All contraindications of the Magnespasmyl or waning/precaution of use as displayed in the respective National Product Labeling that was used for defining these exclusion criteria. Any update of contraindications in labeling document (Magnespasmyl) occuring during the course of the study that should be considered systematically as a new exclusion criterion.
-Pregnant, lactating, or females planning pregnancy in the next year or women with noneffective contraceptive method during the study period.
-Subject who has withdrawn consent before enrollment/randomization.
-Despite screening of the subject, enrollment/randomization is stopped at the study level.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline of DASS-42 Stress subscale |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
a)Change from baseline of DASS-42 Stress subscale
b)Change from baseline of DASS-42 Anxiety subscale
c)Change from baseline of DASS-42 Depression subscale
d)Change from baseline in cortisol awakening response (CAR) measured by the mean over a 2 day of total area under curve AUCt (T0, T30, T45) of CAR
e)Change from baseline in absolute increase of cortisol (AINC) measured by the mean over a 2 day of total area under curve AUCt (T0, T30, T45) of AINC
f)Change from baseline in increase of cortisol (MINC) measured by the mean over a 2 day of total area under curve AUCt (T0, T30, T45) of MINC
g)Change from baseline on erythrocytes magnesium level |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
a) Baseline, 4 weeks
b), c), d), e), f), g) : Baseline, 4 weeks and 8 weeks
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |